Overview: NGS Microphthalmia Anophthalmia Coloboma Sequencing TestIntroduction: The NGS Microphthalmia Anophthalmia Coloboma Sequencing Test sequences genes to diagnose eye malformations, causing vision defects. Following 2023 AAO guidelines, it uses PCR for high specificity, supporting vision screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected microphthalmia, anophthalmia, or coloboma (MAC).
Other Names: MAC Assay, SOX2/OTX2 Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: MAC sequencing began in the 2000s with eye development research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose MAC, guides treatment, and evaluates patients with vision defects.
Test Parameters: 1. MAC Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of vision defects, small eyes, or MAC symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document vision defects, microphthalmia, coloboma, or family history of MAC. Include current medications, especially vision-related treatments.
Consent: Written consent required, detailing the tests purpose, MAC implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze MAC genes (e.g., SOX2, OTX2). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for MAC diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm MAC, guiding surgical correction or genetic counseling. Negative results may require clinical evaluation.
Specialist Consultation: Consult an ophthalmologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Eye exam, orbital imaging, or visual evoked potentials to confirm MAC diagnosis.
Test Limitations: Not all MAC cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAO MAC Guidelines, 2023; Ophthalmology, Williamson KA, 2022.
